Influence of n-octenylsuccinate starch on in vitro permeation of sodium diclofenac across excised porcine cornea in comparison to Voltaren ophtha

被引:28
作者
Baydoun, L [1 ]
Müller-Goymann, CC [1 ]
机构
[1] Tech Univ Carolo Wilhelmina Braunschweig, Inst Pharmazeut Technol, D-38106 Braunschweig, Germany
关键词
n-octenylsuccinate starch; sodium diclofenac; in vitro corneal permeation; haemolysis; Voltaren ophtha;
D O I
10.1016/S0939-6411(03)00036-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of different n-octenylsuccinate starch (AS) formulations, i.e. AS solutions and an AS stabilized emulsion system, on the in vitro corneal permeation behaviour of sodium diclofenac (DfNa) was investigated and compared to the commercial product Voltaren ophtha (VO). Although saturation concentrations of DfNa achieved with polyoxethylene-35-castor oil (POC), which is the solubilizing additive in VO, are higher than those achieved with AS at varying pH values, it was found that AS solutions yield higher DfNa permeation rates than VO or a POC solution. However, permeation is extremely reduced with rising AS concentrations or AS emulsions. Neither pH value (6.5 or 7.4) nor presence of preservative seem to have an impact on permeation activity. In order to assess possible cytotoxic effects of the preparations investigated, red blood cell haemolysis studies were performed with different preparations containing DfNa. None of the tested AS formulations showed significantly high haemolytic data. On the other hand the high in vitro haemolysis obtained with VO is primarily based on an osmotic effect caused by boric acid. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:73 / 79
页数:7
相关论文
共 36 条
[1]  
AGATA M, 1984, ACTA SOC OPHTHALMOL, V88, P61
[2]   PHYSICOCHEMICAL DETERMINANTS OF DRUG DIFFUSION ACROSS THE CONJUNCTIVA, SCLERA, AND CORNEA [J].
AHMED, I ;
GOKHALE, RD ;
SHAH, MV ;
PATTON, TF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (08) :583-586
[3]   INTERACTION OF NSA WITH CYCLODEXTRINS AND HYDROXYPROPYL CYCLODEXTRIN DERIVATIVES [J].
BACKENSFELD, T ;
MULLER, BW ;
KOLTER, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 74 (2-3) :85-93
[4]  
BAYDOUN L, 2000, P 3 WORLD M PHARM BI, P801
[5]  
BAYDOUN L, 2002, P 4 WORLD M PHARM BI, P939
[6]  
BAYDOUN L, 2001, ARCH PHARM PHARM S2, V334, P92
[7]  
BENSON H, 1974, ARCH OPHTHALMOL-CHIC, V91, P313
[8]   A NOVEL ASSAY TO DETERMINE THE HEMOLYTIC-ACTIVITY OF DRUGS INCORPORATED IN COLLOIDAL CARRIER SYSTEMS [J].
BOCK, TK ;
MULLER, BW .
PHARMACEUTICAL RESEARCH, 1994, 11 (04) :589-591
[9]  
BOCK TK, 1994, EUR J PHARM BIOPH S, V40, pS26
[10]   Biopharmaceutical considerations in topical ocular drug delivery [J].
Davies, NM .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2000, 27 (07) :558-562